All In Biotech

Drug Trial Radar · NCT05099549

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Nov 3, 2021

Primary completion

Sep 21, 2023

Study completion Sep 21, 2023

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
Collaborators
Affimed GmbH
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Conditions

  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Advanced Solid Tumor
  • Refractory Tumor
  • Metastatic Tumor

Interventions

  • AFM24Drug

    Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

  • SNK01Biological

    Patient-specific ex-vivo expanded autologous natural killer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1/Dose EscalationTime frame: 28 days starting on cycle 1 day 1
  2. Phase 1/Dose EscalationTime frame: 28 days starting on cycle 1 day 1
  3. Phase 2a/ExpansionTime frame: Up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Sarcoma Oncology Center

    Santa Monica, California

  • University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.